Max Kates , MD

Assistant Professor of Urology and Oncology

Co-Director, Bladder Cancer Multidisplinary Clinic

Address:
James Buchanan Brady Urological Institute Johns Hopkins Hospital 600 N. Wolfe Street, Marburg 401c Baltimore, MD 21287

Appointments: 410-955-6100

Office: 410-614-0009

Email: Mkates@jhmi.edu

Fax: 410-502-7711

Dr. Max Kates is an Assistant Professor of Urology and Oncology within the Brady Urological Institute.  Dr. Kates received his undergraduate degree from Wesleyan University in Connecticut, and his medical degree from Mount Sinai School of Medicine in New York.  During that time he completed a Doris Duke clinical research fellowship in Urologic Oncology at Columbia University, College of Physicians and Surgeons.

Dr Kates has expertise in all areas of urologic oncology, including prostate, bladder, kidney, testicular, and genital cancers.  With training in open, laparoscopic, and robotic surgical approaches, Dr Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy.  He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery.

As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches.

Dr. Kates’ research interests parallel his clinical practice, with an emphasis on novel treatments for cancers of the urinary tract.  He has a particular interest in developing novel therapies for bladder cancer, and has a provisional patent for a novel intravesical chemotherapy he developed with nano-engineer collaborators.  Additionally, Dr Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer.

Dr. Kates has authored more than 70 journal articles in the fields of bladder, prostate, and kidney cancer.  He has won numerous awards, including the American Urologic Association (AUA)  Russell Scott Award, best poster awards from the society of urologic oncology and AUA, and best reviewer from the journal Urologic Oncology.

 



Education and Training

EDUCATION

2018-present               
Fellowship in Urologic Oncology (SUO)
Johns Hopkins Hospital
Baltimore, MD

2013-2018                  
Urologic Surgery Residency
Johns Hopkins Hospital
Baltimore, MD

2012-2013                  
General Surgery Internship
Johns Hopkins Hospital
Baltimore, MD

2007 - 2012                 
M.D
Mount Sinai School of Medicine          
New York, NY

2010 – 2011                
Doris Duke Clinical Research Fellowship     Mentor: James McKiernan
Columbia University College of Physicians and Surgeons
New York, NY

2002 - 2006                             
BA in College of Social Studies (Economics, Politics, History) with High Distinction
Wesleyan University
Middletown, CT

PROFESSIONAL EXPERIENCE

2018- present               
Assistant Professor of Urology
James Buchanan Brady Urological Institute
Johns Hopkins Medical Institutions
Baltimore, MD

2006 – 2007                
Harvard Medical School, Department of Health Policy, Richard Frank, PhD,  
Research Assistant in Health Economics



Publications

Free Access to abstracts at PubMed 

Publications

Peer Reviewed Original Research (Published)

  1. Joice GA, Chappidi MR, Patel HD, Kates M, Sopko NA, Stimson CJ, Pierorazio PM, Bivalacqua TJ. Hospitalization and Readmission Costs after Radical Cystectomy in a Nationally Representative Sample: Does Urinary Reconstruction Matter? BJU Int. 2018 Jun 13.
  2. Yoshida T, Sopko NA, Kates M, Liu X, Joice G, McConkey DJ, Bivalacqua TJ. Three-dimensional  organoid culture reveals involvement of Wnt/β-catenin pathway in proliferation of bladder cancer cells. Oncotarget. 2018 Jan 24;9(13):11060-11070
  3. Chalfin HJ, Kates M, van der Toom EE, Glavaris S, Verdone JE, Hahn NM, Pienta KJ, Bivalacqua TJ, Gorin MA. Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method. Urology. 2018 May;115:82-86.
  4. Ooki A, Begum A, Marchionni L, VandenBussche CJ, Mao S, Kates M, Hoque MO. Arsenic promotes the COX2/PGE2-SOX2 axis to increase the malignant stemness properties of urothelial cells. Int J Cancer. 2018 Jul 1;143(1):113-126.
  5. K Liao RS, Gupta M, Schwen ZR, Patel HD, Kates M, Johnson MH, Hahn NM, McConkey  D, Bivalacqua TJ, Pierorazio PM. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. J Urol. 2018 Jul;200(1):68-73.
  6. Yoshida T, Kates M, Sopko NA, Liu X, Singh AK, Bishai WR, Joice G, McConkey DJ, Bivalacqua TJ. Ex vivo culture of tumor cells from N-methyl-N-nitrosourea-induced bladder cancer in rats: Development of organoids and an immortalized cell line. Urol Oncol. 2018 Apr;36(4):160.e23-160.e32.
  7. Kates M, Date A, Afzal U, Kanvinde P, Babu T, Sopko N, Baras A, Yoshida T, Matsui H, Hanes J, Ensign L, Bivalacqua T Preclincial Evaluation of a Novel Intravesical Cisplatin Nanoformulation for Non–Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2017 Nov 1;23(21):6592-6601
  8. Kates M, Nirschl T, Sopko N, Matsui H, Kochel C, Reis  L, Netto G, Hoque M, Hahn N, McConkey DJ, Baras A, Drake CG, Bivalacqua TJ. Intravesical BCG induces CD4+ T Cell Expansion in a Clinically Relevant Immune Competent Model of Bladder Cancer. Cancer Immunol Res. 2017 Jul;5(7):594-603
  9. Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T, Sankin A, Pierorazio PM, Schoenberg MP, Bivalacqua TJ. Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2017 Oct 27;3(4):293-303.         
  10. Campbell SP, Baras AS, Ball MW, Kates M, Hahn NM, Bivalacqua TJ, Johnson MH, Pomper MG, Allaf ME, Rowe SP, Gorin MA. Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma. Ann Nucl Med. 2017 Oct 24.
  11. Semerjian A, Milbar N, Kates M, Gorin MA, Patel HD, Chalfin HJ, Frank SM, Wu CL, Yang WW, Hobson D, Robertson L, Wick E, Schoenberg MP, Pierorazio PM, Johnson MH, Stimson CJ, Bivalacqua TJ. Hospital Charges and Length of Stay Following Radical Cystectomy in the Enhanced Recovery After Surgery Era.Urology. 2017 Oct 13.
  12. Kates M, Chappidi MR, Brant A, Milbar N, Sopko NA, Meyer C, Terezakis SA, Herman JM, Efron JE, Safar B, Tran PT, Ahuja N, Pierorazio PM, Bivalacqua TJ. High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer. Bladder Cancer. 2017 Jul 27;3(3):191-199.
  13. Pederzoli F, Chappidi MR, Collica S, Kates M, Joice GA, Sopko NA, Montorsi F, Salonia A, Bivalacqua TJ. Analysis of Hospital Readmissions After Prosthetic Urologic Surgery in the United States: Nationally Representative Estimates of Causes, Costs, and Predictive Factors. J Sex Med. 2017 Aug;14(8):1059-1065.
  14. Chappidi MR, Kates M, Sopko NA, Joice GA, Tosoian JJ, Pierorazio PM, Bivalacqua TJ. Erectile Dysfunction Treatment Following Radical Cystoprostatectomy: Analysis of a Nationwide Insurance Claims Database. J Sex Med. 2017 Jun;14(6):810-817.
  15. Chappidi MR, Kates M, Tosoian JJ, Johnson MH, Hahn NM, Bivalacqua TJ, Pierorazio PM. Evaluation of gender-based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims database. BJU Int. 2017 Apr 18
  16. Matsui H, Sopko NA, Hannan JL, Reinhardt AA, Kates M, Yoshida T, Liu X, Castiglione F, Hedlund P, Weyne E, Albersen M, Bivalacqua TJ. M1 Macrophages Are Predominantly Recruited to the Major Pelvic Ganglion of the Rat Following Cavernous Nerve Injury. J Sex Med. 2017 Feb;14(2):187-195.
  17. Chappidi MR, Kates M, Brant A, Baras AS, Netto GJ, Pierorazio PM, Hahn NM, Bivalacqua TJ. Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder Cancer. Urology. 2017 Apr;102:148-158.
  18. Patel HD, Gorin MA, Gupta N, Kates M, Johnson MH, Pierorazio PM, Allaf ME. Mortality trends and the impact of lymphadenectomy on survival for renal cell carcinoma patients with distant metastasis. Can Urol Assoc J. 2016 Nov-Dec;10(11-12):389-395.
  19. Chappidi MR, Chalfin HJ, Johnson DJ, Kates M, Sopko NA, Johnson MH, Liu JJ, Frank SM, Bivalacqua TJ. Longer average blood storage duration is associated with increased risk of infection and overall morbidity following radical cystectomy. Urol Oncol. 2017 Feb;35(2):38.e17-38.e24.
  20. Brant A, Kates M, Chappidi MR, Patel HD, Sopko NA, Netto GJ, Baras AS, Hahn NM, Pierorazio PM, Bivalacqua TJ.  Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT? Urol Oncol. 2016 Sep 14
  21. Chappidi MR, Kates M, Stimson CJ, Johnson MH, Pierorazio PM, Bivalacqua TJ. Causes, Timing, Hospital Costs and Perioperative Outcomes of Index vs Nonindex Hospital Readmissions after Radical Cystectomy: Implications for Regionalization of Care. J Urol. 2016.
  22. Baras AS, Drake C, Liu JJ, Gandhi,N, Kates,M, Hoque,M.O, Meeker,A, Hahn,N,  Taube,J.M, Schoenberg,M.P., Netto,G., Bivalacqua,T.J. The ratio of CD8 to treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology. 2016;5: e1134412.
  23. Chappidi MR, Kates M, Johnson MH, Hahn N, Bivalacqua TJ, Pierorazio PM: Lymph node yield and tumor location in patients with upper tract urothelial carcinoma undergoing nephroureterectomy affects survival: A U.S. population-based analysis (2004-2012). Urol Oncol 2016
  24. Chappidi MR, Kates M, Stimson CJ, Pierorazio PM, Bivalacqua TJ: Quantifying Non-Index Hospital Readmissions and Care Fragmentation Following Major Urologic Oncology Surgeries in a Nationally Representative Sample. J Urol 2016
  25. Gorin MA, Rowe SP, Hooper JE, Kates M, Hammers HJ, Szabo Zet al: PSMA-Targeted 18F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy. Eur Urol 2016
  26. Kates M, Ball MW, Chappidi MR et al: Accuracy of urethral frozen section during radical cystectomy for bladder cancer. Urol Oncol 2016
  27. Kaye DR, Canner JK, Kates M, Schoenberg MP, Bivalacqua TJ. Do african american patients treated with radical cystectomy for bladder cancer have worse overall survival? accounting for pathologic staging and patient demographics beyond race makes a difference. Bl Cancer. 2016;2(2):225-234.
  28. Sopko NA, Matsui H, Lough DM, Miller D, Harris K, Kates M et al. Ex vivo model of human penile transplantation and rejection: Implications for erectile tissue physiology. Eur Urol. 2016.
  29. Kryvenko ON, Diaz M, Matoso A, Kates M, Cohen J, Swanson GP, Epstein JI.  Prostate-specific Antigen Mass Density-A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution. Urology. 2016 Apr;90:141-7.
  30. Chappidi MR, Kates M, Patel HD, Tosoian JJ, Kaye DR, Sopko NA, Lascano D, Liu JJ, McKiernan J, Bivalacqua TJ. Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomy. Urol Oncol. 2016.
  31. Kates M, Sopko NA, Han M, Partin AW, Epstein JI. Importance of Reporting The Gleason Score at the Positive Surgical Margin Site: An Analysis of 4,082 Consecutive Radical Prostatectomy Cases. J Urol. 2016 Feb;195(2):337-42
  32. Lascano D, Pak JS, Kates M, Finkelstein JB, Silva M, Hagen E, et al. Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools. Urol Oncol. 2015 Oct;33(10):426.e1-12
  33. Joice GA, Kates M, Sopko NA, Hannan JL, Bivalacqua TJ. Sickle Cell Disease in Priapism: Disparity in Care?. Urology 2015;86 72-9.
  34. Gandhi NM, Baras A, Munari E, Faraj S, Reis LO, Liu JJ, Kates M, et al. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urol.Oncol. 2015;33 204.e1,204.e7.
  35. Deibert CM, Kates M, McKiernan JM, Spencer BA. National estimated costs of never events following radical prostatectomy. Urol.Oncol. 2015;33 385.e1,385.e6.
  36. Patel HD, Ball MW, Cohen JE, Kates M, Pierorazio PM, Allaf ME. Morbidity of urologic surgical procedures: an analysis of rates, risk factors, and outcomes..  Urology. 2015; 85 (3): 552-560.
  37. Gorin MA, Kates M, Mullins JK, Pierorazio PM, Matlaga BR, Schoenberg MP, et al. Impact of hospital volume on perioperative outcomes and costs of radical cystectomy: Analysis of the Maryland health services cost review commission database. Can J Urol. 2014 Feb;21(1):7102-7.
  38. Kates M, Ball MW, Patel HD, Gorin MA, Pierorazio PM, Allaf ME. The financial impact of robotic technology for partial and radical nephrectomy. J Endourol. 2014 Oct 10.
  39. Kates M, Gorin MA, Deibert CM, Pierorazio PM, Schoenberg MP, McKiernan JM, et al. In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the united states. Urol Oncol. 2014 Jan;32(1):53.e9,53.14.
  40. Kates M, Tosoian JJ, Trock BJ, Feng Z, Carter HB, Partin AW. Indications for intervention during active surveillance of prostate cancer: A comparison of the Johns Hopkins and prostate cancer research international active surveillance (PRIAS) protocols. BJU Int. 2014 Jun 6.
  41. McKiernan JM, Holder DD, Ghandour RA, Barlow LJ, Ahn JJ, Kates M, et al. Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus calmette-guerin treatment failure. J Urol. 2014 Dec;192(6):1633-8.
  42. Patel HD, Kates M, Pierorazio PM, Allaf ME. Race and sex disparities in the treatment of older patients with T1a renal cell carcinoma: A comorbidity-controlled competing-risks model. Urol Oncol. 2014 Jul;32(5):576-83.
  43. Patel HD, Kates M, Pierorazio PM, Allaf ME. Balancing cardiovascular (CV) and cancer death among patients with small renal masses: Modification by CV risk. BJU Int. 2014 Mar 3.
  44. Patel HD, Kates M, Pierorazio PM, Gorin MA, Jayram G, Ball MW, et al. Comorbidities and causes of death in the management of localized T1a kidney cancer. Int J Urol. 2014 Nov;21(11):1086-92.
  45. Joice GA, Deibert CM, Kates M, Spencer BA, McKiernan JM. "Never events": Centers for medicare and medicaid services complications after radical cystectomy. Urology. 2013 Mar;81(3):527-32.
  46. Kates M, Whalen MJ, Badalato GM, McKiernan JM. The effect of race and gender on the surgical management of the small renal mass. Urol Oncol. 2013 Nov;31(8):1794-9.
  47. Tsao CK, Small AC, Kates M, Moshier EL, Wisnivesky JP, Gartrell BA, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the united states: A SEER analysis. World J Urol. 2013 Dec;31(6):1535-9.
  48. Badalato GM, Gaya JM, Hruby G, Patel T, Kates M, Sadeghi N, et al. Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: Is there a survival difference? BJU Int. 2012 Nov;110(10):1471-7.
  49. Badalato GM, Kates M, Wisnivesky JP, Choudhury AR, McKiernan JM. Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: A propensity scoring approach. BJU Int. 2012 May;109(10):1457-62.
  50. Kates M, Badalato GM, Gupta M, McKiernan JM. Secondary bladder cancer after upper tract urothelial carcinoma in the US population. BJU Int. 2012 Nov;110(9):1325-9.
  51. Kates M, Korets R, Sadeghi N, Pierorazio PM, McKiernan JM. Predictors of locally advanced and metastatic disease in patients with small renal masses. BJU Int. 2012 May;109(10):1463-7.
  52. Kates M, Lavery HJ, Brajtbord J, Samadi D, Palese MA. Decreasing rates of lymph node dissection during radical nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2012 Aug;19(8):2693-9.
  53. Pitman M, Korets R, Kates M, Hruby GW, McKiernan JM. Socioeconomic and clinical factors influence the interval between positive prostate biopsy and radical prostatectomy. Urology. 2012 Nov;80(5):1027-32.  
  54. Sadeghi N, Badalato GM, Hruby G, Kates M, McKiernan JM. The impact of perioperative blood transfusion on survival following radical cystectomy for urothelial carcinoma. Can J Urol. 2012 Oct;19(5):6443-9.
  55. Shapiro, M., Mhango, G., Kates, M., Weiser, T. S., Chin, C., Swanson, S. J., & Wisnivesky, J. P. Extent of lymph node resection does not increase perioperative morbidity and mortality after surgery for stage I lung cancer in the elderly.2012. European Journal of Surgical Oncology (EJSO), 38(6), 516-522.
  56. Kates M, Badalato G, Pitman M, McKiernan J. Persistent overuse of radical nephrectomy in the elderly. Urology. 2011 Sep;78(3):555-9.
  57. Kates M, Badalato GM, Pitman M, McKiernan JM. Increased risk of overall and cardiovascular mortality after radical nephrectomy for renal cell carcinoma 2 cm or less. J Urol. 2011 Oct;186(4):1247-53.
  58. Kates M, Swanson S, Wisnivesky JP. Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer<=1 cm in size: A review of SEER data. Chest. 2011 Mar;139(3):491-6.
  59. Korets R, Graversen JA, Kates M, Mues AC, Gupta M. Post-percutaneous nephrolithotomy systemic inflammatory response: A prospective analysis of preoperative urine, renal pelvic urine and stone cultures. J Urol. 2011 Nov;186(5):1899-903.
  60. Kates M, Perez X, Gribetz J, Swanson SJ, McGinn T, Wisnivesky JP. Validation of a model to predict perioperative mortality from lung cancer resection in the elderly. Am J Respir Crit Care Med. 2009 Mar 1;179(5):390-5.

Other Peer-Reviewed Articles

  • Kates M, Drake C. Immunotherapy for Prostate Cancer: Why Now. Urology Practice. In Press
  • Kates M, Sopko NA, Matsui H, Drake CG, Hahn NM, Bivalacqua TJ. Immune checkpoint inhibitors: a new frontier in bladder cancer. World J.Urol. 2015.
  • Sopko NA, Kates M, Bivalacqua TJ. Use of regenerative tissue for urinary diversion. Curr.Opin.Urol. 2015;25 578-85.
  • Kates M, Singh A, Matsui H, Steinberg GD, Smith ND, Schoenberg MP, Bivalacqua TJ. Tissue Engineered Urinary Conduits.  Current Urology Reports. 2015; 16 (3):480-485.
  • Kates M, Matlaga BR. Stones in the elderly. Current Geriatrics Reports. 2014;3(1):14-8.
  • Kates M, Badalato GM, McKiernan JM. Renal functional outcomes after surgery for renal cortical tumors. Curr Opin Urol. 2011 Sep;21(5):351-5.
  • Sadeghi N, Badalato GM, Kates M, McKiernan JM. Management of residual non-retroperitoneal disease following chemotherapy for germ cell tumor. Urol Oncol. 2011 Nov-Dec;29(6):837-41.

Book Chapters

  • Badalato GM, Kates M. Sadeghi N, and McKiernan JM. Renal Cortical Neoplasms and Associated Renal Functional Outcomes, Diseases of Renal Parenchyma. 2012. Prof. Manisha Sahay (Ed.), ISBN: 978-953-51-0245-8, InTech.
  • Kates M, Carter H.B., Macura, K.  MRI and Active Surveillance, MRI of the Prostate. 2016. In Press, Thieme Publishers.

 

Invited Editorials:

  • Kates M, McKiernan J. Reply to editorial. 2012 Urology.78:560.
  • Kates MR, Wisnivesky JP. Author reply to a letter. American Journal of Respiratory and Critical Care Medicine. 2009.180: 794-5

SELECT ABSTRACTS & INVITED PRESENTATIONS (1st Author Only)

Kates M, Matoso A, Baras A, Brant A, Hahn N, McConkey D, Drake C, Bivalacqua T.  An Assessment of immune checkpoint expression among patients with NMIBC undergoing intravesical BCG: Implications for ongoing randomized trials. (Poster Presentation, 1st prize) American Urologic Association (AUA) Annual Meeting, San Francisco. Spring 2018.

Kates M, Nirschl T, Sopko N, Matsui H, Kochel C, Reis  L, Netto G, Hoque M, Hahn N, McConkey DJ, Baras A, Drake CG, Bivalacqua TJ. Intravesical BCG induces CD4+ T Cell Expansion in a Clinically Relevant Immune Competent Model of Bladder Cancer. (Poster Presentation, 1st prize) Society of Urologic Oncology (SUO) Annual Meeting, San Antonio, Winter 2016.

Kates M, Date A, Afzal U, Kanvinde P, Babu T, Sopko N, Baras A, Yoshida T, Matsui H, Hanes J, Ensign L, Bivalacqua T Preclincial Evaluation of a Novel Intravesical Cisplatin Nanoformulation for Non–Muscle-Invasive Bladder Cancer. (Poster Presentation) Society of Urologic Oncology (SUO) Annual Meeting, San Antonio, Winter 2016.

“Utility of Urethral Frozen Sections During Radical Cystectomy for Bladder Cancer.” Kates M, Ball M, Chappidi M, Sopko N, Pierorazio P, Bivalacqua T, Schoenberg M. (Podium Presentation). American Urologic Association (AUA) Annual Meeting, San Diego. Spring 2016.

“Local T Lymphocyte Sub-Population Responses to Intravesical BCG and Chemoetherapy in an immune competent murine model of bladder cancer.” Kates M, Sopko N, Matsui H, Liu Xiaopu, Reis L, Hahn N, Baras A, Kochel C, Drake C, Bivalacqua T (Poster Presentation).  American Urologic Association (AUA) Annual Meeting, San Diego. Spring 2016.

“Nanoparticle Approaches to Improving the Immunologic Response to Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer” Max Kates. Talk Given at the 2015 BCAN Bladder Cancer Think Tank.

“Validation of the Modified Frailty Index to Predict Adverse Outcomes after Cystectomy. Kates M, Patel H, Joice G, Tosoian J, Sopko N, Bivalacqua T.” (Poster Presentation). Society of Urologic Oncology (SUO) Annual Meeting, Bethesda, Winter 2014.

“Indications for intervention during active surveillance of prostate cancer: A comparison of the Johns Hopkins and prostate cancer research international active surveillance (PRIAS) protocols.” Kates M, Tosoian JJ, Trock BJ, Feng Z, Carter HB, Partin AW. American Urologic Association (AUA) Annual Meeting, Orlando., Spring 2014.

“Cardiovascular Comorbidity and Survival Among Medicare Beneficiaries undergoing Treatment for a Small Renal Masses.” Kates, M Pierorazio, P,Patel, H, Jayram G, Allaf M.American Urologic Association (AUA) Annual Meeting, San Diego., Spring 2013.

“Increased Risk of Overall and Cardiovascular Mortality after  Radical Nephrectomy for Renal Cell Carcinoma ≤2cm” Kates M. Badalato G, Pitman M, McKiernan J. (Poster Presentation, presented by Neda Sadeghi).  American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Summer 2011 .

“The Persistent Overuse of Radical Nephrectomy in the Elderly.” Kates M. Badalato G, Pitman M, McKiernan J. (Podium Presentation).   American Urologic Association (AUA) Annual Meeting, Washington D.C., Spring 2011 .

“Age and Gender Predicts Risk of Non-localized Disease in Small Renal Tumors ≤3cm in size.” Kates M. Korets R, Sadeghi N, Pierorazio P, McKiernan J (Podium Presentation).  American Urologic Association (AUA) Annual Meeting, Washington D.C., Spring 2011 .

“Partial vs Radical Nephrectomy in the treatment of Localized Renal Cell Carcinoma 4-7cm in Size: A Propensity Scoring Approach” Kates M, Badalato G, Wisnivesky J, RoyChoudhury A, McKiernan J (Podium Presentation).   American Urologic Association (AUA) Annual Meeting, Washington D.C., Spring 2011 .

“The Impact of Ureteroscopy on the Rate of Secondary Bladder Cancer in the United State: A Population-Based Assessment” Kates M, Badalato G, Yeshchina O, Sadeghi N, McKiernan J. (Podium Presentation, presented by G. Badalato).   American Urologic Association (AUA)Annual Meeting, Washington D.C., Spring 2011 .

“The Use of Radical Nephrectomy in the Elderly.” Kates M. (Oral Presentation).  The New York Section, American Urological Association. 61st Annual Valentine Essay Meeting, New York, Spring 2011.

“Pathologic Stage at Prostatectomy over Time: Has There Been a Trend toward Intervention for Localized Disease in the Robotic Era?”  Kates M, Badalato G, Hruby G, Sadeghi N, Benson M, McKiernan J. (Extended Poster Presentation). European Association of Urology (EAU) Annual Meeting, Vienna, Austria, Spring 2011.

“Predictors of Locally-Advanced and Metastatic Disease in Renal Cell Carcinoma £3cm in Size: A Population Based Analysis.” Kates M, Korets R, Sadeghi N, McKiernan J. (Poster Presentation).  Society of Urologic Oncology (SUO) Annual Meeting, Bethesda, Winter 2010.

“Survival Following Partial and Radical Nephrectomy for the Treatment of Stage IB Renal Cell Carcinoma: A Propensity Scoring Approach” Kates M, Badalato G, Wisnivesky J, RoyChoudhury A, McKiernan J (Poster Presentation). Society of Urologic Oncology (SUO) Annual Meeting, Bethesda, Winter 2010.

“Decreasing Rates of Lymphadenectomy during Radical Nephrectomy for Renal Cell Carcinoma: 1988-2005” Kates MR, Lavery H, Brajtbord J, Samadi D, Palese M.  (Podium Presentation).  American Urologic Association Annual Meeting, San Francisco, Spring 2010.

“Managing Diabetic Complications” Kates M. (Oral Presentation). Mount Sinai EHHOP Grand Rounds. Spring 2010.

 “Outcomes Following Lobectomy and Limited Resection for the Treatment of Stage 1 Lung Cancer ≤ 1cm in Size.” Kates MR, Swanson SJ, Wisnivesky JP. (Oral Presentation) Mount Sinai Medical Student Annual Research Day, New York, Winter 2009

“Outcomes Following Lobectomy and Limited Resection for the Treatment of Stage 1 Lung Cancer ≤ 1cm in Size.” Kates MR, Swanson SJ, Wisnivesky JP. (Poster Session) American College of Surgeons 95th Annual Clinical Congress, Medical Student Program, Chicago, Fall 2009

“Validation of a Model to Predict Perioperative Mortality from Lung Cancer Resection in the Elderly”
Kates MR, Perez X, Gribetz J, Swanson SJ, McGinn T, Wisnivesky JP. American Thoracic Society Conference, (Roundtable Poster Discussion) San Diego, Spring 2009

 



Memberships

PROFESSIONAL SERVICE

International Activities

  • Grant Reviewer, Medical Research Council (MRC), United Kingdom 2016

                                   
National Activities

  • Participant, Biology of Bladder Cancer Workshop, National Cancer Institute, Bethesda, MD June 2018

Ad Hoc Editorial Review Activities

  • Journal of Urology
  • Urologic Oncology
  • Urology
  • BJUI

Professional Societies

  • American Urological Association


Awards & Honors

                                                      
2018American Urological Association Annual Meeting 1st prize Poster Award
2016, 2017 Best Reviewer Urologic Oncology: Seminars and Original Investigations
2016Society of Urologic Oncology Annual Meeting 1st prize Poster Award
2016 Mid-Atlantic AUA Resident Essay Prize
2015 Bladder Cancer Advocacy Network (BCAN) John Quale Travel Fellow
2015 Johns Hopkins Septembeard Research Scholar Award
2015 AUA Urology Care Foundation Russell W Scott Resident Scholar
2015 Brady Urological Institute resident researcher of the year
2014 Johns Hopkins Walter and Lucille Rubin Research Award
2012 Harold Lamport Biomedical Research Award
2012 Distinction in Research, Mount Sinai School of Medicine
2011 Gold Humanism Honor Society, Mount Sinai School of Medicine
2011 Alpha Omega Alpha (AΩA) Honor Medical Society, Mount Sinai School of Medicine
2006 Team Captain, Wood Memorial Award, Wesleyan University Tennis Team
2005 Finalist, Truman Scholar
2004 Mount Sinai School of Medicine Humanities and Medicine Scholar